Cullinan Therapeutics Inc
CGEM
NASDAQ
Biotechnology
$20.34
USD
+0.70 (+3.56%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.26B
Volume 565.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-204.69M
TTM
+1.0%
YoY
Operating Cash Flow
$-159.25M
TTM
+7.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 14.8 | 13.6 | 12.3 | 11.6 | 12.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 75.8 | 55.6 | 55.3 | 53.7 | 57.3 |
Operating Income | -75.8 | -55.6 | -55.3 | -53.7 | -57.3 |
EBITDA | -75.7 | -55.5 | -55.2 | -53.6 | -57.2 |
Other Income / Expense | -0.2 | -0.1 | -0.1 | -0.1 | -0.1 |
Total Other Income / Expense | 5.7 | 5.0 | 4.5 | 4.0 | 3.6 |
Income Before Income Taxes | -70.1 | -50.6 | -50.7 | -49.7 | -53.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -70.1 | -50.6 | -50.7 | -49.7 | -53.7 |
Consolidated Net Income / Loss | -70.1 | -50.6 | -50.7 | -49.7 | -53.7 |
Net Income Attributable to Common Shareholders | -70.1 | -50.6 | -29.0 | -45.5 | -53.7 |
Basic EPS | -$1.19 | -$0.86 | -$0.49 | -$0.75 | -$0.87 |
Diluted EPS | -$1.19 | -$0.86 | -$0.49 | -$0.75 | -$0.87 |
Basic Shares Outstanding | 59.0M | 59.1M | 59.2M | 60.5M | 61.5M |
Diluted Shares Outstanding | 59.0M | 59.1M | 59.2M | 60.5M | 61.5M |